Novartis: launch of Morphosys drug by could be 2027 or later
Portfolio Pulse from
Novartis' CEO announced that the launch of the blood-cancer drug pelabresib, acquired from Morphosys, could be delayed until 2027 or later, pending further safety data.
November 21, 2024 | 8:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novartis' potential launch of the blood-cancer drug pelabresib may be delayed until 2027 or later, depending on further safety data.
The delay in the launch of pelabresib could impact Novartis' future revenue projections, but the dependency on safety data makes the immediate impact on stock price uncertain. Investors may view this as a neutral development until more information is available.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80